Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers.
about
Nucleotide metabolism, oncogene-induced senescence and cancer.Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers.High expression of ribonucleotide reductase subunit M2 correlates with poor prognosis of hepatocellular carcinoma.The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients.Ribonucleotide reductase subunit M2 predicts survival in subgroups of patients with non-small cell lung carcinoma: effects of gender and smoking statusGenome Wide Expression Profiling of Cancer Cell Lines Cultured in Microgravity Reveals Significant Dysregulation of Cell Cycle and MicroRNA Gene NetworksMolecular profile of 5-fluorouracil pathway genes in colorectal carcinoma.Colorectal Cancer: Basic and Translational Research.in silico analyses of metabolic pathway and protein interaction network for identification of next gen therapeutic targets in Chlamydophila pneumoniaeIncreased LEF1 expression and decreased Notch2 expression are strong predictors of poor outcomes in colorectal cancer patients.Cell cycle dependent RRM2 may serve as proliferation marker and pharmaceutical target in adrenocortical cancerPrognostic and therapeutic value of mitochondrial serine hydroxyl-methyltransferase 2 as a breast cancer biomarkerIdentification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancerIncreased expression of RRM2 by human papillomavirus E7 oncoprotein promotes angiogenesis in cervical cancerLncSubpathway: a novel approach for identifying dysfunctional subpathways associated with risk lncRNAs by integrating lncRNA and mRNA expression profiles and pathway topologies.Targeting ribonucleotide reductase for cancer therapy.Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies.Ribonucleotide reductase large subunit M1 plays a different role in the invasion and metastasis of papillary thyroid carcinoma and undifferentiated thyroid carcinoma.Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers.KLHL39 suppresses colon cancer metastasis by blocking KLHL20-mediated PML and DAPK ubiquitination.RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy.Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach.Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy.A ribonucleotide reductase inhibitor with deoxyribonucleoside-reversible cytotoxicity.Repositioning of a cyclin-dependent kinase inhibitor GW8510 as a ribonucleotide reductase M2 inhibitor to treat human colorectal cancer.p53R2 overexpression in cervical cancer promotes AKT signaling and EMT, and is correlated with tumor progression, metastasis and poor prognosis.Knockdown of TBRG4 affects tumorigenesis in human H1299 lung cancer cells by regulating DDIT3, CAV1 and RRM2.Downregulation of ribonucleotide reductase subunits M2 induces apoptosis and G1 arrest of cervical cancer cells.miR-211 regulates the expression of RRM2 in tumoral metastasis and recurrence in colorectal cancer patients with a k-ras gene mutation.siRNA Knockdown of RRM2 Effectively Suppressed Pancreatic Tumor Growth Alone or Synergistically with Doxorubicin
P2860
Q33969333-09478AFF-779F-4DBD-B882-1645CCDCA721Q34227409-C9E22A21-8E37-4C77-BE99-138537EA7CCAQ34432197-1351AE68-194D-438B-8D92-10F089C3912EQ35123132-3AC84677-6EB8-4B4D-A823-623C680C4B37Q35637007-3AC17EF9-A29A-4C57-BD1B-610BDBCD4243Q35752214-AEE45D0E-8F15-4070-8BD3-9EA65ACBFB17Q36161868-877F8CDF-A846-4395-B21D-89EB876001ACQ36281589-93406477-66BE-4C4E-97F3-E5D813A45C93Q37049216-46981F0A-88F5-4245-B6EE-7CF4FF236315Q37260274-3FFDE9E3-17BB-497D-8AE2-212CE8C7C842Q37298315-47E218C7-A968-43DE-A48C-FD60FA67E2B8Q37321209-A6AC1E68-3330-485B-8A5E-CCBF649E71D5Q37529964-4A02969F-C004-47A1-891B-4445DF1CD64FQ37594412-012A1321-F5C6-466F-9B14-EEEADAB408EAQ37716567-7D26BBAF-DB88-4192-8FC0-A666CE8ECDCFQ38148222-F2F2A34E-7E92-436D-AD2B-779FCDA83817Q38218536-218C43A3-597E-4A51-9CE2-E92E371A0456Q38829129-588F2509-3490-40EE-BF98-3A047BF7022DQ38853361-E0F79811-70F7-497A-A7BB-0EAAA1093D18Q38916626-ED0C3E99-B387-4139-9B4E-40A2E970DC4BQ39146064-B47FFB0A-3D1A-4C8E-958A-9822DC3EF0F9Q39283216-3DD3CD1C-29E2-44CA-9FA4-BD64ED2D49F5Q39327140-18C9C25B-2408-4661-99CB-1A62FF638D9EQ42282773-6A809975-B514-470B-9426-A4B9C4D6D23DQ42367853-CCF07B66-B974-47F5-AF03-7A8B7872432FQ47906170-8D072AFB-926D-4951-AABE-ABC0F9F6F80BQ49465492-76F144BB-8155-4DF3-B420-E29587817585Q52725569-8741530D-3E64-4372-BEB4-6AEF3C182AB3Q54983378-809DC526-49B3-42E6-A5D6-11CF3344ECB8Q58795137-FE0FAC86-08E8-48B7-A11B-E7062B1FD7DF
P2860
Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Ribonucleotide reductase small ...... urvival of colorectal cancers.
@ast
Ribonucleotide reductase small ...... urvival of colorectal cancers.
@en
type
label
Ribonucleotide reductase small ...... urvival of colorectal cancers.
@ast
Ribonucleotide reductase small ...... urvival of colorectal cancers.
@en
prefLabel
Ribonucleotide reductase small ...... urvival of colorectal cancers.
@ast
Ribonucleotide reductase small ...... urvival of colorectal cancers.
@en
P2093
P2860
P356
P1433
P1476
Ribonucleotide reductase small ...... survival of colorectal cancers
@en
P2093
Bingsen Zhou
Hang Zhang
Keqiang Zhang
Peiguo Chu
Rebecca A Nelson
P2860
P304
P356
10.1042/CS20120240
P407
P50
P577
2013-05-01T00:00:00Z